This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
In phase 3 trials, Jyseleca was shown to be effective in reducing the symptoms of RA, including joint tenderness and swelling. ... FINCH 3 compared Jyseleca alone or in combination with methotrexate as a front-line therapy for patients with
3.Excellence in Global Education Meetings/Stand-Alone Events. Sponsored by HEALTH UNLIMITED. Winner: LiBRA 2019: Looking Beyond the Joint in Rheumatoid Arthritis (RA): Is There a Missing Link in RA
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... ICER also presented concerns over the long-term impact of
AbbVie has been betting on its new products upadacitinib for RA and Skyrizi for psoriasis to combat Humira’s decline. ... If approved in Europe, AbbVie could begin to reclaim Humira’s lost ground in RA.
Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s ... well-regarded JAK1 inhibitor
New approach to tackling diseases such as lupus, RA. Dutch biotech Citryll has raised 15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.
More from news
Approximately 9 fully matching, plus 152 partially matching documents found.
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed.
LiBRA is a multichannel program, focused on inspiring and enabling clinical behavior change to achieve better disease control for patients with RA. ... Lisa Druce, Managing Director, Lighthouse Medical Communications US, commented “RA is a chronic
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS –
LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?
Geneva:. World Health Organisation; 2003. 7. Ward BW, Schiller JS, Goodman RA. ... Yugoslavia: discussion paper. J R Soc Med 1991; 84:288–291. 27. Boza RA, Milanes F, Slater V, Garrigo L, Rivera CE.
More from PMHub
Approximately 2 fully matching, plus 28 partially matching documents found.
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...